Published in Schizophr Bull on January 01, 2003
Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ (2008) 9.98
Randomized controlled trials for schizophrenia: study designs targeted to distinct goals. Schizophr Bull (2008) 0.78
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med (2005) 28.99
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry (2006) 3.72
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry (2011) 2.52
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. Br J Psychiatry (2006) 2.24
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry (2011) 2.15
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry (2009) 1.70
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. J Clin Psychiatry (2012) 1.67
Determining when impairment constitutes incapacity for informed consent in schizophrenia research. Br J Psychiatry (2007) 1.56
What CATIE found: results from the schizophrenia trial. Psychiatr Serv (2008) 1.55
Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract (2006) 1.48
Tobacco use and mental illness: a wake-up call for psychiatrists. Psychiatr Serv (2014) 1.42
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res (2008) 1.37
Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry (2008) 1.37
Informing sequential clinical decision-making through reinforcement learning: an empirical study. Mach Learn (2011) 1.35
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis (2006) 1.32
Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull (2003) 1.30
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res (2005) 1.28
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res (2005) 1.20
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology (2010) 1.19
Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr Bull (2010) 1.13
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biol Psychiatry (2007) 1.10
NCAM1 and neurocognition in schizophrenia. Biol Psychiatry (2006) 1.10
Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv (2006) 1.09
The NIMH-CATIE Schizophrenia Study: what did we learn? Am J Psychiatry (2011) 1.07
The impact of obesity on health care costs among persons with schizophrenia. Gen Hosp Psychiatry (2008) 1.02
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. Am J Med Genet B Neuropsychiatr Genet (2008) 0.97
The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res (2011) 0.95
Polypharmacy for schizophrenia. Curr Opin Psychiatry (2013) 0.94
New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. Int J Epidemiol (2015) 0.93
Substance use and schizophrenia: adverse correlates in the CATIE study sample. Schizophr Res (2011) 0.89
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry (2009) 0.87
Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry (2012) 0.86
AKT1 and neurocognition in schizophrenia. Aust N Z J Psychiatry (2007) 0.86
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res (2008) 0.86
A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet (2010) 0.84
Effects of antipsychotic medication on psychiatric service utilization and cost. J Ment Health Policy Econ (2005) 0.84
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry (2012) 0.84
Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Rev Pharmacoecon Outcomes Res (2007) 0.84
Paliperidone for treatment of schizophrenia. Schizophr Bull (2008) 0.84
Service use and health status of persons with severe mental illness in full-risk and no-risk medicaid programs. Psychiatr Serv (2002) 0.83
Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). Front Genet (2011) 0.82
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry (2010) 0.82
No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. Am J Med Genet B Neuropsychiatr Genet (2010) 0.80
Assessment of Medicaid managed behavioral health care for persons with serious mental illness. Psychiatr Serv (2005) 0.80
Paliperidone palmitate for schizophrenia. Schizophr Bull (2012) 0.78
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. J Behav Health Serv Res (2008) 0.78
Public-academic partnerships: a rapid small-grant program for policy-relevant research: motivating public-academic partnerships. Psychiatr Serv (2013) 0.77
Schizophrenia, VI: Treatments. Am J Psychiatry (2003) 0.77
Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv (2014) 0.77
Electronic health records in mental health research: a framework for developing valid research methods. Psychiatr Serv (2014) 0.76
What can large simple trials do for psychiatry? Am J Psychiatry (2011) 0.76
Medications for first-episode psychosis: making a good start. Am J Psychiatry (2015) 0.76
Schizophrenia, drug therapy, and monitoring. N Engl J Med (2004) 0.75
Response to Rosenfeld. Am J Psychiatry (2014) 0.75
Criminal justice system involvement among people with schizophrenia. Community Ment Health J (2010) 0.75
The need to determine the best options for people with schizophrenia that is unresponsive to treatment. Rev Psiquiatr Salud Ment (2012) 0.75